OBJECTIVE: Treatment options are still limited in patients with cisplatin-refractory and multiply relapsed germ cell tumors. We evaluated the efficacy and tolerability of lenalidomide within a compassionate use concept. PATIENTS AND METHODS: Four patients multiply relapsed after platin-based chemotherapies without any further standard treatment option received 25 mg lenalidomide orally on days 1-21 of a 28-day cycle. RESULTS: All four patients were pretreated with a median number of seven lines of previous chemotherapy (range 4-8), all including platin-based high-dose chemotherapy. After 4 weeks of lenalidomide treatment all patients had progressive disease with increase in serum tumor markers and progression in computed tomography. Median survival time was 8 weeks (range 5-17). The toxicity profile was favorable. No severe toxicities related to lenalidomide occurred in these patients. CONCLUSION: Lenalidomide was well tolerated but did not show efficacy in heavily pretreated patients with cisplatin-refractory and multiply relapsed germ cell tumors.
OBJECTIVE: Treatment options are still limited in patients with cisplatin-refractory and multiply relapsed germ cell tumors. We evaluated the efficacy and tolerability of lenalidomide within a compassionate use concept. PATIENTS AND METHODS: Four patients multiply relapsed after platin-based chemotherapies without any further standard treatment option received 25 mg lenalidomide orally on days 1-21 of a 28-day cycle. RESULTS: All four patients were pretreated with a median number of seven lines of previous chemotherapy (range 4-8), all including platin-based high-dose chemotherapy. After 4 weeks of lenalidomide treatment all patients had progressive disease with increase in serum tumor markers and progression in computed tomography. Median survival time was 8 weeks (range 5-17). The toxicity profile was favorable. No severe toxicities related to lenalidomide occurred in these patients. CONCLUSION:Lenalidomide was well tolerated but did not show efficacy in heavily pretreated patients with cisplatin-refractory and multiply relapsed germ cell tumors.
Authors: C Bokemeyer; A Gerl; P Schöffski; A Harstrick; N Niederle; J Beyer; J Casper; H J Schmoll; L Kanz Journal: J Clin Oncol Date: 1999-02 Impact factor: 44.544
Authors: C Kollmannsberger; O Rick; H-G Derigs; N Schleucher; P Schöffski; J Beyer; R Schoch; H G Sayer; A Gerl; M Kuczyk; C Spott; L Kanz; C Bokemeyer Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: C Bokemeyer; J Beyer; B Metzner; U Ruther; A Harstrick; L Weissbach; U Kohrmann; W Verbeek; H J Schmoll Journal: Ann Oncol Date: 1996-01 Impact factor: 32.976
Authors: Christoph Oing; Winfried H Alsdorf; Gunhild von Amsberg; Karin Oechsle; Carsten Bokemeyer Journal: World J Urol Date: 2016-07-23 Impact factor: 4.226